Compare Mesoblast Limited (MESO) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Charles Schwab Corporation Common Stock — how do they compare? Mesoblast Limited trades at $16.96 (market cap $2.21B), while Charles Schwab Corporation Common Stock trades at $108.18 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 84.3× Mesoblast Limited's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SCHW | |
|---|---|---|
Market Cap | $2.21B | $186.25B |
Sector | Technology | Financials |
52-Week High | $20.96 | $108.02 |
52-Week Low | $12.88 | $85.35 |
Enterprise Value | $2.21B | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Charles Schwab (SCHW) trades at $107.99, up 0.36% today, near its all-time high. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels suggest overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with EPS of $1.62 versus $1.56 expected, and revenue growth accelerated to $23.92 billion in 2025. Analyst sentiment remains positive with a 56.87% buy rating and a $122.33 consensus price target, indicating potential upside.
The outlook for SCHW is favorable given robust earnings performance and upward revenue guidance, but risks include potential market volatility from economic data and ongoing litigation. Institutional buying and a high ROE of 22.45% support the bullish case, though investors should monitor inflation reports and insider selling activity for near-term cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
